reported that the combination of AFP-L3 and glypican-3 (GPC3) achieved high diagnostic accuracy for low-AFP HCC patients, because single detection with AFP-L3 may not be sensible and accurate (16, 17). Here, GPC3 is linked to hepatocellular carcinoma.